Quarterly ResultMay 5, 2026, 06:53 AM
BioNTech Q1 Revenue €118.1M, Net Loss €531.9M
AI Summary
BioNTech SE reported a significant decline in its financial performance for the first quarter ended March 31, 2026. Revenues decreased by 35.4% to €118.1 million, primarily due to lower COVID-19 vaccine sales. The company's net loss widened to €531.9 million, an increase of 27.9% compared to the prior year, driven by higher R&D expenses and an impairment loss of €37.7 million, mainly related to the BNT331 program. Despite the losses, BioNTech maintained a strong liquidity position with €16,763.3 million in cash, cash equivalents, and security investments.
Key Highlights
- Revenues decreased 35.4% to €118.1 million for Q1 2026 from €182.8 million in Q1 2025.
- Net loss increased 27.9% to €531.9 million for Q1 2026 from €415.8 million in Q1 2025.
- Basic and diluted loss per share was €2.10 for Q1 2026, up from €1.73 in Q1 2025.
- COVID-19 vaccine revenues declined 49.7% to €66.9 million in Q1 2026 from €133.0 million.
- Research and development expenses increased 6.0% to €557.0 million in Q1 2026.
- Recognized impairment losses of €37.7 million, including €29.9 million for product candidate BNT331.
- Total cash, cash equivalents, and security investments were €16,763.3 million as of March 31, 2026.
- Operating loss increased to €677.5 million for Q1 2026 from €534.1 million in Q1 2025.
Price Impact
More from BNTX